Pharmacophore modeling and virtual screening studies to identify novel selective SIRT2 inhibitors.

Sirtuins (SIRTs) are a class of NAD+-dependent protein histone deacetylases (HDACs) that catalyse the reversible deacetylation of lysine residues in the histones or non-histone substrates. Mammalian sirtuins consist of seven isoforms (SIRT1-7), which show different subcellular localizations and enzymatic functions. Among the seven human sirtuins, SIRT2 predominantly located in the cytoplasm but is enriched in the nucleus during mitosis. Its activity has been found to be modulate the pathophysiology of various diseases such as cancer, metabolic and neurodegenerative disorders. Therefore, selective SIRT2 inhibitors are of growing interest as potentially candidate therapeutic agents to treat SIRT2-driven pathologies as well as valuable tools to investigate and define the biological roles of SIRT2. Herein, in order to identify potent leads against SIRT2, a multi-step pharmacophore based-virtual screening campaign was performed and 31 predicted compounds were subjected to in vitro biological evaluation. Finally, compound 2 and 3 showing better SIRT2 inhibition potency were selected for further in vitro cytotoxic assays against a panel of three human cancer cell lines. This study will hopefully provide a basis for developing potent and selective SIRT2 inhibitors.

• Publication year

  2019

• Venue

  Journal of Molecular Graphics and Modelling

• Publication date

  2019-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.jmgm.2019.02.014PMID 30870650
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An overview of Sirtuins as potential therapeutic target: Structure, function and modulators.

  2019cited by this paper
• X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.

  2018cited by this paper
• Identification of a cellularly active SIRT6 allosteric activator

  2018cited by this paper
• Crystal structure of Sirt2 in complex with selective inhibitor A2I

  2018cited by this paper
• SIRT2 deacetylase represses NFAT transcription factor to maintain cardiac homeostasis

  2018cited by this paper
• SIRT2 inhibition modulate glutamate and serotonin systems in the prefrontal cortex and induces antidepressant‐like action

  2017cited by this paper
• Thienopyrimidinone Based Sirtuin-2 (SIRT2)-Selective Inhibitors Bind in the Ligand Induced Selectivity Pocket

  2017cited by this paper
• Development of 1,2,4-Oxadiazoles as Potent and Selective Inhibitors of the Human Deacetylase Sirtuin 2: Structure-Activity Relationship, X-ray Crystal Structure, and Anticancer Activity.

  2017cited by this paper
• Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure-Activity Relationship Analysis

  2017cited by this paper
• Potent mechanism-based sirtuin-2-selective inhibition by an in situ-generated occupant of the substrate-binding site, “selectivity pocket” and NAD+-binding site

  2017cited by this paper
• Synthesis and Evaluation of Novel Benzofuran Derivatives as Selective SIRT2 Inhibitors

  2017cited by this paper
• A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity.

  2016cited by this paper
• A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity.

  2016cited by this paper
• SIRT2- and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington's Disease Models.

  2016cited by this paper
• Aminothiazoles as Potent and Selective Sirt2 Inhibitors: A Structure-Activity Relationship Study.

  2016cited by this paper
• In Search of New Therapeutic Targets in Obesity Treatment: Sirtuins

  2016cited by this paper
• Structure-Based Development of an Affinity Probe for Sirtuin 2.

  2016cited by this paper
• 5-((3-Amidobenzyl)oxy)nicotinamides as Sirtuin 2 Inhibitors.

  2016cited by this paper
• Identification of a Selective SIRT2 Inhibitor and Its Anti-breast Cancer Activity.

  2016cited by this paper
• AK-1, a specific SIRT2 inhibitor, induces cell cycle arrest by downregulating Snail in HCT116 human colon carcinoma cells.

  2015cited by this paper
• Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.

  2015cited by this paper
• Poly(ADP-ribose) polymerase (PARP)-based pharmacophore model development and its application in designing antitumor inhibitors

  2015cited by this paper
• Emerging Role of Sirtuin 2 in the Regulation of Mammalian Metabolism.

  2015cited by this paper
• Selective Inhibition of SIRT2 Improves Outcomes in a Lethal Septic Model

  2015cited by this paper
• SIRT2 is involved in the modulation of depressive behaviors

  2015cited by this paper
• The role of sirtuins in cardiac disease.

  2015cited by this paper
• Chronic stress and antidepressant induced changes in Hdac5 and Sirt2 affect synaptic plasticity.

  2015cited by this paper
• Sirtuins in Epigenetic Regulation

  2015cited by this paper
• Selective Sirt2 inhibition by ligand-induced rearrangement of the active site

  2015cited by this paper
• The Discovery of a Highly Selective 5,6,7,8‐Tetrahydrobenzo[4,5]thieno[2,3‐d]pyrimidin‐4(3H)‐one SIRT2 Inhibitor that is Neuroprotective in an in vitro Parkinson’s Disease Model

  2015cited by this paper
• Design and Evaluation of 3-(Benzylthio)benzamide Derivatives as Potent and Selective SIRT2 Inhibitors.

  2015cited by this paper
• Chroman-4-one- and chromone-based sirtuin 2 inhibitors with antiproliferative properties in cancer cells.

  2014cited by this paper
• Synthesis and evaluation of novel benzimidazole derivatives as sirtuin inhibitors with antitumor activities.

  2014cited by this paper
• SIRT2: tumour suppressor or tumour promoter in operable breast cancer?

  2014cited by this paper
• Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors.

  2014cited by this paper
• Identification of novel SIRT2-selective inhibitors using a click chemistry approach.

  2014cited by this paper
• Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach.

  2014cited by this paper
• The tumor suppressor SirT2 regulates cell cycle progression and genome stability by modulating the mitotic deposition of H4K20 methylation.

  2013cited by this paper
• Evaluation and Optimization of Virtual Screening Workflows with DEKOIS 2.0 - A Public Library of Challenging Docking Benchmark Sets

  2013cited by this paper
• A Novel Sirtuin 2 (SIRT2) Inhibitor with p53-dependent Pro-apoptotic Activity in Non-small Cell Lung Cancer*

  2013cited by this paper
• HDAC6 and SIRT2 Regulate the Acetylation State and Oncogenic Activity of Mutant K-RAS

  2013cited by this paper
• Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3.

  2013cited by this paper
• SIRT2 as a Therapeutic Target for Age-Related Disorders

  2012cited by this paper
• SIRT2 activity is required for the survival of C6 glioma cells.

  2012cited by this paper
• The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models.

  2012cited by this paper
• Ammonia-containing dimethyl sulfoxide: an improved solvent for the dissolution of formazan crystals in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay.

  2012cited by this paper
• A Molecular Mechanism for Direct Sirtuin Activation by Resveratrol

  2012cited by this paper
• Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.

  2012cited by this paper
• SIRT2 is a tumor suppressor that connects aging, acetylome, cell cycle signaling, and carcinogenesis.

  2012cited by this paper
• Dietary obesity-associated Hif1α activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+ system.

  2012cited by this paper
• Interactomic and Pharmacological Insights on Human Sirt-1

  2012cited by this paper
• SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity.

  2011cited by this paper
• HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin.

  2011cited by this paper
• A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase.

  2011cited by this paper
• Sirtuins at a glance

  2011cited by this paper
• SIRT Inhibitors Induce Cell Death and p53 Acetylation through Targeting Both SIRT1 and SIRT2

  2010cited by this paper
• Oxadiazole-carbonylaminothioureas as SIRT1 and SIRT2 inhibitors.

  2008cited by this paper
• Virtual Screening Using PLS Discriminant Analysis and ROC Curve Approach: An Application Study on PDE4 Inhibitors

  2008cited by this paper
• Characterization of the binding properties of SIRT2 inhibitors with a N-(3-phenylpropenoyl)-glycine tryptamide backbone.

  2008cited by this paper
• SIRT2 suppresses adipocyte differentiation by deacetylating FOXO1 and enhancing FOXO1's repressive interaction with PPARgamma.

  2008cited by this paper
• Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests.

  2008cited by this paper
• Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.

  2007cited by this paper
• Evaluating Virtual Screening Methods: Good and Bad Metrics for the "Early Recognition" Problem

  2007cited by this paper
• Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease

  2007cited by this paper
• The role of nuclear architecture in genomic instability and ageing

  2007cited by this paper
• A therapeutic role for sirtuins in diseases of aging?

  2007cited by this paper
• Sirtuin functions in health and disease.

  2007cited by this paper
• Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.

  2006cited by this paper
• PHASE: A Novel Approach to Pharmacophore Modeling and 3D Database Searching

  2006cited by this paper
• N,N'-Bisbenzylidenebenzene-1,4-diamines and N,N'-Bisbenzylidenenaphthalene-1,4-diamines as Sirtuin Type 2 (SIRT2) Inhibitors.

  2006cited by this paper
• Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes.

  2006cited by this paper
• Sirtuins as potential targets for metabolic syndrome

  2006cited by this paper
• Functional significance of histone deacetylase diversity.

  2001cited by this paper
• Principal component analysis

  1987cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper

• Multilayered screening for multi-targeted anti-Alzheimer’s and anti-Parkinson’s agents through structure-based pharmacophore modelling, MCDM, docking, molecular dynamics and DFT: a case study of HDAC4 inhibitors

  2025cites this paper
• Targeting SIRT2 with Oxadiazole/Thiadiazole-Based Acetamides: In Silico Screening and In Vitro Cytotoxicity Evaluation

  2025cites this paper
• SIRT2 Inhibition promotes microglia LC3-associated phagocytosis via NRF2/CD36 after the experimental subarachnoid hemorrhage

  2025cites this paper
• Linker and tail group modifications on 2-((4-isopropyl-4H-1,2,4-triazol-3-yl)thio)-N-(4-phenoxyphenyl)acetamide to improve SIRT2 inhibitory potency

  2024cites this paper
• Symmetrical 2,7‐disubstituted 9H‐fluoren‐9‐one as a novel and promising scaffold for selective targeting of SIRT2

  2024cites this paper
• 2‐(Methyl(phenyl)amino)‐N‐(phenyloxyphenyl)acetamide structural motif representing a framework for selective SIRT2 inhibition

  2024cites this paper
• Recent Advances in the Discovery of SIRT1/2 Inhibitors via Computational Methods: A Perspective

  2024cites this paper
• Selective inhibition of SIRT2: A disputable therapeutic approach in cancer therapy.

  2023cites this paper
• Trypanosoma cruzi Sirtuin 2 as a Relevant Druggable Target: New Inhibitors Developed by Computer-Aided Drug Design

  2023cites this paper
• In silico approach reveals N-(5-phenoxythiophen-2-yl)-2-(arylthio)acetamides as promising selective SIRT2 inhibitors: the case of structural optimization of virtual screening-derived hits

  2023influential citation
• Hit evaluation results in 5-benzyl-1,3,4-thiadiazole-2-carboxamide based SIRT2-selective inhibitor with improved affinity and selectivity.

  2022cites this paper
• Design and synthesis of amino acid derivatives of substituted benzimidazoles and pyrazoles as Sirt1 inhibitors

  2022cites this paper
• From Traditional Herbal Medicine to Rational Drug Discovery: Strategies, Challenges, and Future Perspectives

  2022cites this paper
• Virtual Screening in the Identification of Sirtuins’ Activity Modulators

  2022influential citation
• SIRT1 and SIRT2 Activity Control in Neurodegenerative Diseases

  2021cites this paper
• Selective SIRT2 inhibitors as promising anticancer therapeutics: An update from 2016 to 2020.

  2021cites this paper
• Mechanism-based inhibitors of SIRT2: structure–activity relationship, X-ray structures, target engagement, regulation of α-tubulin acetylation and inhibition of breast cancer cell migration

  2021cites this paper
• The potential of 4-aryl-6-morpholino-3(2H)-pyridazinone-2-arylpiperazinylacetamide as a new scaffold for SIRT2 inhibition: in silico approach guided by pharmacophore mapping and molecular docking

  2021cites this paper
• Selective inhibitors of SIRT2 regulate perinuclear α-tubulin acetylation, migration, and invasion of breast cancer cells

  2020cites this paper
• Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs

  2020cites this paper
• Hit-to-lead optimization on aryloxybenzamide derivative virtual screening hit against SIRT.

  2020cites this paper
• Improved method of structure-based virtual screening based on ensemble learning

  2020cites this paper
• Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening.

  2019cites this paper
• Molecular docking, pharmacophore based virtual screening and molecular dynamics studies towards the identification of potential leads for the management of H. pylori

  2019cites this paper